[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uti\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uti":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,88,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100621586","effect-of-voiding-position-standing-in-the-shower-vs-sitting-on-post-void-residual-urine-volume-pvr-after-removal-of-urinary-catheter-in-women-following-benign-vaginal-gynecologic-surgery-100621586",false,"NCT07372547","Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery","Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery: A Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult women (≥18 years old).\n* Undergoing benign vaginal gynecologic surgery with indwelling catheter during surgery.\n* No bladder injury during surgery.\n* Ability and willingness to consent.\n* No known neurological or urinary conditions affecting voiding.\n* No active urinary tract infection at time of catheter removal.\n\nExclusion Criteria:\n\n* Bladder injury during surgery.\n* Neurological disease affecting bladder function.\n* Active urinary tract infection.\n* Inability to void either standing in shower or sitting (depending on randomization).","FEMALE","18 Years","99 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if voiding in a standing position in the shower, rather than sitting on a toilet, may reduce pain associated with the act of voiding, thereby facilitating micturition and decreasing both post-void residual volume and the risk of subsequent urinary retention in women that underwent benign vaginal surgeries.",[27,28,29,30,31],"Post-void Residual Volume","Recatheterization","Pain","UTI","Urinary Retention","RECRUITING","2026-03-22",{"date":35,"type":36},"2026-03-25","ACTUAL",{"date":38,"type":36},"2026-01-20",{"date":40,"type":21},"2028-01-20",{"name":42,"class":43},"Assuta Ashdod Hospital","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":68,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100588378","a-trial-of-d-mannose-for-the-prophylaxis-of-recurrent-urinary-tract-infections-100588378","NCT06940622","A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections","A Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal Women","DmannoseRCT","Inclusion Criteria:\n\n* Female, post-menopausal, age ≥ 55 years old\n* Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\\\u003C103 colony forming units per ml of urine).\n* Able to attend all follow-up appointments for the study.\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n\nExclusion Criteria:\n\n* Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.\n* Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.\n* Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.\n* Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank\u002Flumbar pain or tenderness\n* Diagnosis of interstitial cystitis or overactive bladder syndrome\n* Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months\n* Use of Uromune or other vaccine approaches to reduce rUTI\n* Participation in a research study involving an investigational product in the past 12 weeks\n* Receipt of phage treatment\n* History of chronic diarrhea requiring regular therapy\n* Inability to swallow or known history of gastrointestinal malabsorption\n* History of recurrent vaginal yeast infections\n* Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \\[creatinine \\> 1.5 g\u002Fdl\\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet).\n* Nursing home resident\n* BMI \\>40\n\nBox 1 Supplements to avoid\n\n* Multi-Vitamins and Multi-Mineral capsules\n* Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen)\n* Probiotics\n* Cranberry Mannose or Cranberry Extract Weight loss products to avoid\n* Medifast\n* Vitafusion\n* OptiVin Products\n* Appetite Suppressants\n* Keto-Fuel","55 Years","85 Years",{"count":56,"type":21},90,[24],"A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.",[60,61,62,63,64,65,30,66,67],"Recurrent UTIs","Recurrent Urinary Tract Infections","Recurrent Urinary Tract Infections in Women","Recurrent Urinary Tract Infection","Cystitis Recurrent","Cystitis Chronic","UTI - Urinary Tract Infection","UTI - Lower Urinary Tract Infection",[69,70,71,72,73,74,75,76,77],"D-mannose","dmannose","uti","ruti","recurrent urinary tract infection","urinary tract infection","cystitis","chronic uti","chronic cystitis","2025-09-18",{"date":80,"type":36},"2025-09-22",{"date":82,"type":36},"2025-08-01",{"date":84,"type":21},"2030-09-30",{"name":86,"class":43},"University of Texas Southwestern Medical Center",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":87},"100582169","value-of-infection-control-programs-on-infection-associated-with-urinary-tract-catheterization-in-sohag-university-hospital-100582169","NCT06859814","Value of Infection Control Programs on Infection Associated with Urinary Tract Catheterization in Sohag University Hospital","Urinary tract","Inclusion Criteria:\n\nAdult patients (≥ 18 years) who are catheterized during their hospitalization. Patients who provide informed consent to participate in the study.\n\nExclusion Criteria:\n\nPatients with a known history of urinary tract infections prior to hospitalization.\n\nPatients who have indwelling catheters for more than 14 days before the study. Patients with urinary tract anomalies or other conditions that may affect infection rates.","ALL",{"count":97,"type":21},200,[24],"The aim of this study is to evaluate the effectiveness of an infection control program implemented at Sohag University Hospital in reducing the incidence of catheter-associated urinary tract infections (CAUTIs) among patients requiring urinary catheterization.",[30],[30,102],"Urinary catheterization","2025-03-05",{"date":105,"type":36},"2025-03-10",{"date":107,"type":36},"2025-02-01",{"date":82,"type":21},{"name":110,"class":43},"Sohag University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":95,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":87},"100420437","antibiotic-usage-prior-to-onabotulinumtoxina-injection-100420437","NCT04754737","Antibiotic Usage Prior to OnabotulinumtoxinA Injection","Optimizing Antibiotic Use in Treatment of Overactive Bladder: Evaluating the Need for Prophylactic Antibiotics Prior to OnabotulinumtoxinA Injection in Patients Without Urinary Tract Infection","Inclusion Criteria:\n\n* Age ≥ 18\n* Diagnosis of OAB who have failed 1st and 2nd line therapies per the AUA\u002FSUFU OAB guidelines (including bladder training, dietary modification and pharmacotherapy with an anticholinergic and\u002For beta-3 agonist)\n* Not symptomatic for UTI at the time of injection\n* Negative urinalysis at the time of the injection defined as: negative for nitrites and leukocyte esterace, with urine white blood cell count less than 5 per high-power field\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Antibiotic usage within 48 hours prior to intradetrusor onabotulinumtoxinA injection\n* Women who are pregnant or planning to become pregnant, women who are breastfeeding\n* Concurrent use of onabotulinumtoxinA injection with maximum cumulative dose exceeding 400 units in a 3-month interval.",true,{"count":97,"type":21},[24],"Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onabotulinumtoxinA is currently standard of care of patients with OAB who have persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure. However, these recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate. A previously published prospective study demonstrated that the rate of post-procedural UTI did not differ amongst patients with neurogenic bladder who did not receive prophylactic antibiotics and were asymptomatic for UTI, regardless of whether they had sterile urine cultures or asymptomatic bacteriuria, suggesting that patients who are not symptomatic for UTI may not require antibiotic prophylaxis prior to intradetrusor onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal\u002Fallergic and gastro-intestinal manifestations. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally evaluate the differences in UTI frequency in subjects who have a negative urinalysis and are not symptomatic for UTI and receive prophylactic antibiotics at the time of intradetrusor onabotulinumtoxinA injection compared to those who do not receive prophylactic antibiotics at the time of injection. The proposed study seeks to evaluate the current practice standard of antibiotic prophylaxis prior to intradetrusor onabotulinumtoxin injection.",[123,124,125,30],"Antibiotic Stewardship","Overactive Bladder","Onabotulinumtoxin A","2024-05-23",{"date":128,"type":36},"2024-05-24",{"date":130,"type":36},"2021-03-23",{"date":132,"type":21},"2026-12",{"name":134,"class":43},"Benaroya Research Institute"]